Download full-text PDF

Source

Publication Analysis

Top Keywords

disseminated breast
4
breast cancer
4
cancer current
4
current responses
4
responses cytotoxic
4
cytotoxic drugs
4
disseminated
1
cancer
1
current
1
responses
1

Similar Publications

[Solid, endometrial-like and transitional growth patterns of ovarian high-grade serous carcinoma: a clinicopathological analysis of 25 cases].

Zhonghua Bing Li Xue Za Zhi

February 2025

Department of Pathology, the Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou 215002, China.

To investigate the clinicopathological characteristics of solid, endometrial-like and transitional (SET) cell growth subtype in high-grade serous ovarian carcinoma (HGSC). Clinical data of 25 cases of HGSC-SET were collected from January 2020 to March 2024 at the Affiliated Suzhou Hospital of Nanjing Medical University, and their histological features were analyzed. Immunohistochemical stains were used to analyze the expression of ER, PR, PAX8, WT-1, p16, p53 and Ki-67.

View Article and Find Full Text PDF

Resistance to Radiotherapy in Cancer.

Diseases

January 2025

Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia.

Radiation therapy or radiotherapy is a medical treatment that uses high doses of ionizing radiation to eliminate cancer cells and shrink tumors. It works by targeting the DNA within the tumor cells restricting their proliferation. Radiotherapy has been used for treating cancer for more than 100 years.

View Article and Find Full Text PDF

Clinical application of third-generation dual-source CT-based dynamic imaging reconstruction for pulmonary embolism imaging.

J Cardiothorac Surg

January 2025

Department of Thyroid Breast Cardiothoracic & Vascular Surgery, Beibei District Hospital of Traditional Chinese Medicine, No. 380 Jiangjun Road, Beibei District, Chongqing, 400700, China.

Background: To evaluate the clinical diagnostic value of third-generation dual-source CT for pulmonary embolism, focusing on the optimization of dual-source CT scanning with dynamic reconstruction in acute pulmonary embolism (PE) and various imaging manifestations.

Methods: Eighty-two patients with pulmonary embolism were enrolled and randomly divided into standard CT angiography (SCTA) and dynamic CT angiography (DCTA). DCTA patients were divided into dynamic CT angiography arterial phase (DCTAa), time phase Angiography reconstruction (TMIP-CTA), and 4D noise reduction TMIP-CTA according to the image reconstruction.

View Article and Find Full Text PDF

Introduction: Breast cancer is the most common and deadliest cancer in Syria, and early detection is crucial in managing it. This study aims to compare the knowledge levels of breast cancer risk factors, signs, and symptoms among female students in healthcare faculties (medicine, dentistry, and pharmacy) at Damascus University to identify existing disparities. The goal is to enhance breast cancer education and awareness across Syria by empowering healthcare students with insights.

View Article and Find Full Text PDF

Targeting murine metastatic cancers with cholera toxin A1-adjuvanted peptide vaccines.

Hum Vaccin Immunother

December 2025

TIMM Laboratory, Sahlgrenska Center for Cancer Research, Department of Microbiology and Immunology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

The dissemination of tumor cells with ensuing metastasis is responsible for most cancer-related deaths. Cancer vaccines may, by inducing tumor-specific effector T cells, offer a strategy to eliminate metastasizing tumor cells. However, several obstacles remain in the development of effective cancer vaccines, including the identification of adjuvants that enhance the evolvement and efficacy of tumor-specific T cells.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!